These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17571262)

  • 1. Oral arsenic trioxide therapy for acute promyelocytic leukemia before and after liver transplantation for hepatitis B virus-related liver failure.
    Au WY; Liu CL; Tam S; Fong BM; Shek TW; Hui CK; Kwong YL
    Ann Hematol; 2007 Oct; 86(10):771-2. PubMed ID: 17571262
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with acute promyelocytic leukemia treated with arsenic trioxide.
    Yujiri T; Tanaka M; Taguchi A; Tanaka Y; Nakamura Y; Tanizawa Y
    Ann Hematol; 2014 Feb; 93(2):351-2. PubMed ID: 23728611
    [No Abstract]   [Full Text] [Related]  

  • 3. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
    Yoon HS; Park TS; Jeong KH
    Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902
    [No Abstract]   [Full Text] [Related]  

  • 4. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
    Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
    Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
    Tedeschi A; Cairoli R; Marenco P; Nosari A; Tresoldi E; Di Bona E; Montillo M; Morra E
    Leukemia; 2002 Dec; 16(12):2455-6. PubMed ID: 12454753
    [No Abstract]   [Full Text] [Related]  

  • 6. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
    Yamakura M; Tsuda K; Ugai T; Sugihara H; Nisihida Y; Takeuchi M; Matsue K
    Acta Haematol; 2014; 131(2):76-7. PubMed ID: 24081111
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 8. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
    Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 11. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
    Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
    Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
    Au WY; Cheung GT; Yuen TW; Kumana CR; Kwong YL
    Arch Intern Med; 2005 May; 165(9):1067-8. PubMed ID: 15883249
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
    Ishitsuka K; Shirahashi A; Iwao Y; Shishime M; Takamatsu Y; Takatsuka Y; Utsunomiya A; Suzumiya J; Hara S; Tamura K
    Eur J Haematol; 2004 Apr; 72(4):280-4. PubMed ID: 15089767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
    Kajiguchi T; Yamamoto K; Sawa M; Emi N; Naoe T
    Leukemia; 2005 Apr; 19(4):674-6. PubMed ID: 15690072
    [No Abstract]   [Full Text] [Related]  

  • 16. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
    Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
    Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
    [No Abstract]   [Full Text] [Related]  

  • 17. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expanding role of arsenic in acute promyelocytic leukemia.
    Tallman MS
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis.
    Zhou J; Meng R; Sui X; Meng L; Jia J; Yang B
    Haematologica; 2005 Sep; 90(9):1277-9. PubMed ID: 16154855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.